An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
AK Singh, A Singh, R Singh, A Misra - Diabetes & Metabolic Syndrome …, 2022 - Elsevier
Background and aims Molnupiravir is a newer oral antiviral drug that has recently received
emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on …
emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on …
Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records
Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …
The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)
P Pagliano, C Sellitto, T Ascione… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Molnupiravir (MOV) is a broad-spectrum oral antiviral agent approved for the
treatment of COVID-19. The results from in vitro and in vivo studies suggested MOV activity …
treatment of COVID-19. The results from in vitro and in vivo studies suggested MOV activity …
[HTML][HTML] Antiviral efficacy and safety of molnupiravir against omicron variant infection: a randomized controlled clinical trial
R Zou, L Peng, D Shu, L Zhao, J Lan, G Tan… - Frontiers in …, 2022 - frontiersin.org
Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has
unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved …
unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved …
Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19)
Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents
CA Gentry, P Nguyen, SK Thind, G Kurdgelashvili… - Journal of infection, 2023 - Elsevier
Objectives Molnupiravir and nirmatrelvir/ritonavir each became available in the United
States (US) through the Food and Drug Administration (FDA) emergency use authorization …
States (US) through the Food and Drug Administration (FDA) emergency use authorization …
[HTML][HTML] Molnupiravir when used alone seems to be safe and effective as outpatient COVID-19 therapy for hemodialyzed patients and kidney transplant recipients
P Poznański, H Augustyniak-Bartosik, A Magiera-Żak… - Viruses, 2022 - mdpi.com
Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …
Effectiveness of molnupiravir and nirmatrelvir–ritonavir in hospitalized patients with COVID-19: a target trial emulation study
Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19： a meta-analysis
W Wen, C Chen, J Tang, C Wang, M Zhou… - Annals of …, 2022 - Taylor & Francis
Background The coronavirus disease (COVID-19) epidemic has not been completely
controlled. Although great achievements have been made in COVID-19 research and many …
controlled. Although great achievements have been made in COVID-19 research and many …
[HTML][HTML] Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
K Rosenke, MC Lewis, F Feldmann, E Bohrnsen… - JCI insight, 2023 - ncbi.nlm.nih.gov
The periodic emergence of SARS-CoV-2 variants of concern (VOCs) with unpredictable
clinical severity and ability to escape preexisting immunity emphasizes the continued need …
clinical severity and ability to escape preexisting immunity emphasizes the continued need …